Inventors
Zeng Jun, Claude, Eric Berk, Jonathan P, Mavericks, Zhang Min, Bolan, Ned Sai Kaen, Liu Xiaolin, Yu Dechao
Assignees
- Cinda Biopharmaceutical (Suzhou) Co., Ltd.
Abstract
The present invention provides an antibody that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), an antigen-binding fragment of the antibody, and a composition comprising the antibody or the fragment. Also provided are a nucleic acid that encodes the antibody or the fragment, a host cell containing the nucleic acid, and applications of the antibody and the fragment in treatment and diagnosis..
CovalX Technology Used
Outcomes
An antibody/antigen complex was prepared using the following concentrations:
|
People of PCSK9 (PCSK9-WT) |
PCSK9 |
Complex |
||||
|
1 |
5μL |
8 μM |
5 μL |
1 μM |
10 μL |
0.5 μM/4 μM |
1 μL of the antibody/antigen complex was mixed with 1 μL of sinapic acid matrix (10 mg/ml in acetonitrile/water (1:1, v/v) with 0.1% TFA) before 1 μL of the final mixture was plated on a MALDI target and allowed to crystallize at room temperature before being analyzed. The remaining 9 μL of the CovalX K200 Stabilization Kit were mixed with 1 μL of the antibody/antigen complex and incubated at room temperature for 180 minutes to allow for the cross-linking reaction to proceed. In order to characterize the complex, a mass spectrometer that had been modified with a CovalX HM4 detection system was used. The data was analyzed using the CovalX Complex Tracker software. From this analysis, researchers determined that PCSK9-WT is reduced and that the PCSK9-WT anti-PCSK9 antibody can bind.
In another experiment, the same antibody/antigen complex was created and 1mg of deuterated DSS (d12) from CovalX was used as part of the cross-linking reaction. 1 mg of DSS (d0) and 1 mg of the deuterated DSS (d12) were mixed with 1 ml of DMF. 10 μL of the d0 agent was mixed with the antibody/antigen complex as well as 1 μL of the d12 agent before being incubated at room temperature for 180 minutes to allow for the cross-linking reaction to proceed.
Patent Number
WO2018/113781 A1